© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.
Virbac announces the launch of TULISSIN Injectable Solution in the US
Virbac will market TULISSIN cattle products directly and its swine products through a partnership with Pharmgate.
Virbac is slated to launch its first product in the US food production animal market after receiving FDA approval of TULISSIN (Tulathromycin injectable) Injectable Solution for use in cattle and swine.
According to the release, TULISSIN 100 Injectable Solution offers a concentration of 100 mg/mL and will be available in 50-, 100-, 250-, and 500-mL bottles. TULISSIN 25 Injectable Solution offers a concentration of 25 mg/mL and will come in 100- and 250-mL bottles.1 Virbac will market the cattle products with its own direct sales force.
In addition, the swine products will be marketed through an agreement with Pharmgate.
"We are excited to collaborate with a reputable animal health organization, such as Virbac, as they launch a range of products into the US large animal market," says Ed Seed, head of Global Sales & Marketing for Pharmgate, in the release.
"Adding this initial product, TULISSIN, to our portfolio over the coming year will expand our offering in fulfilling our customers' complete therapeutic product needs," continued Seed.
Virbac currently has a major presence in the large animal health segment in several regions, including Asia, Pacific, Europe, and Latin America. What's more, this product will be Virbac’s first to entry into this segment of the US market.
"We see the market authorization of TULISSIN as a major accomplishment and are excited about our introduction into the food-producing animal market for the US. I am convinced that Pharmgate, with its broad portfolio of products and strong field team, key relationships, and expertise, is a perfect fit for Virbac to successfully enter the swine segment," said Francois Fournier, president & CEO, Virbac North America.
Reference
- Virbac announces the approval of TULISSIN® (Tulathromycin injectable) in the US and a collaboration with Pharmgate. PR Newswire. Accessed November 13, 2021. https://www.prnewswire.com/news-releases/virbac-announces-the-approval-of-tulissin-tulathromycin-injectable-in-the-us-and-a-collaboration-with-pharmgate-301439539.html
